Cyclorgdfv

Cyclorgdfv

SCHEMBL30636069

CC(C)C1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC1=O

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 20/20 0.78
ITGAV P06756 15/20 0.78
ITGB5 P18084 8/20 0.76
ITGA2B P08514 7/20 0.76
ITGB6 P18564 3/20 0.76
ITGA5 P08648 3/20 0.70
ITGB1 P05556 2/20 0.70
ITGB8 P26012 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclorgdfv SCHEMBL29384091 1.00 ITGB3 (0.78) ITGB3ITGAVITGB5ITGA2BITGB6
SCHEMBL31294830 0.92 ITGB3 (0.80) ITGB3ITGAVITGB5ITGA2BITGA5
SCHEMBL30098352 0.91 ITGB3 (0.76) ITGB3ITGAVITGB5ITGA2BITGA5
SCHEMBL29464836 0.89 ITGB3 (0.75) ITGB3ITGAVITGB5ITGA2BITGA5
SCHEMBL29578997 0.89 ITGB3 (0.75) ITGB3ITGAVITGB5ITGA2BITGA5
SCHEMBL29366713 0.88 ITGB3 (0.74) ITGB3ITGAVITGB5ITGA2BITGA5
SCHEMBL30129817 0.88 ITGB3 (0.81) ITGB3ITGAVITGB5ITGA2BITGB6
SCHEMBL17364341 0.88 ITGB3 (0.74) ITGB3ITGAVITGB5ITGA2BITGA5
Cilengitide SCHEMBL19534260 0.87 ITGB3 (0.78) ITGB3ITGAVITGB5ITGA2BITGB6
Cilengitide SCHEMBL34082 0.87 ITGB3 (0.78) ITGB3ITGAVITGB5ITGA2BITGB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116981479-A FAP-activated radiation therapy diagnostic method and use relating thereto 塔夫茨大学信托人 2023-10-31 CN claimed
CN-116981479-A FAP-activated radiation therapy diagnostic method and use relating thereto 塔夫茨大学信托人 2023-10-31 CN disclosed